In:
BioMed Research International, Hindawi Limited, Vol. 2018 ( 2018-08-27), p. 1-8
Abstract:
Thymosin β 4 (T β 4) treatment was known to show the potential therapeutic effects on diabetic complications. This study was performed to determine if T β 4 expression is changed in both serum and tissues under diabetic conditions and can be a serum biomarker. Type 1 diabetic mice were induced in C57/BL6J mice by intraperitoneal injection of streptozotocin (STZ) at a dose of 50 mg/kg body weight. The mice were sacrificed at 16 weeks after STZ injection. Tissues and plasmas were obtained to determine the expression levels of T β 4 using ELISA, real time RT-PCR, and immunohistochemistry. The average serum glucose level was increased to approximately 400 mg/dL beginning 2 weeks after the five injections of STZ and lasting for at least 13 weeks until sacrifice. The plasma and tissue levels of T β 4 in the age-matched control mice were not significantly different from those of the diabetic mice. In conclusion, the T β 4 expression level in the plasmas and tissues of diabetic mice was not affected by diabetic conditions. It indirectly suggests that the therapeutic effect of T β 4 on diabetic complications is due to its regenerative effects on damaged tissue but not to the changed expression level of T β 4 in plasma and tissues of diabetes.
Type of Medium:
Online Resource
ISSN:
2314-6133
,
2314-6141
DOI:
10.1155/2018/3421568
Language:
English
Publisher:
Hindawi Limited
Publication Date:
2018
detail.hit.zdb_id:
2698540-8